Skip to content

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

NEI Research News

Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.

Source
63 items

Eye cells "rewire" themselves when vision begins to fail

A new study funded by the National Eye Institute shows that certain retinal cells can rewire themselves when vision begins to deteriorate in retinitis pigmentosa, a genetic eye disease that leads to progressive blindness.

Repurposing a high blood pressure drug may prevent vision loss in inherited blinding diseases

New studies in rats suggest the drug reserpine, approved in 1955 for high blood pressure, might treat the blinding disease retinitis pigmentosa. No therapy exists for this rare inherited disease, which starts affecting vision from childhood.

NIH researchers develop eye drops that slow vision loss in animals

Researchers at the National Institutes of Health (NIH) have developed eye drops that extend vision in animal models of a group of inherited diseases that lead to progressive vision loss in humans, known as retinitis pigmentosa.
Decorative

U. Minnesota researchers discover potential new pathway to prevent age-related macular degeneration

The team identified small molecules that can reduce the production of proteins linked to age-related macular degeneration.
Retinal cross section with photoreceptors and nuclei stained

ALG6 acts as a modifier gene in the inherited genetic eye disease retinitis pigmentosa 59

Variant of ALG6 delays rod photoreceptor degradation but decreases cone health in people with RP59 retinitis pigmentosa, according to a new study from University of Alabama, Birmingham.

Researchers closing in on genetic treatments for hereditary lung disease, vision loss

Researchers who work with tiny drug carriers known as lipid nanoparticles have developed a new type of material capable of reaching the lungs and the eyes, an important step toward genetic therapy for hereditary conditions like inherited vision loss.
fMRI of dog brain showing bright activation in the visual cortex.

Using fMRI, new vision study finds promising model for restoring cone function

Researchers have found that in dogs, fMRI can detect brain responses to daylight vision for black and white information as well as color information, and identify the area of the visual cortex that responds to stimulation of a cone-rich retinal region.

Putting regenerative therapies on the map

Members of the National Eye Institute's Audacious Goals Initiative (AGI) published an outline of milestones to reach before commencing clinical trials of regenerative therapies for retinal disease.

Stanford Medicine researchers build an eye ‘aging clock’ that could lead to treatments for ocular diseases

Using a technique they developed for studying eye fluid, Stanford Medicine researchers and their collaborators have found a way to measure ocular aging, opening avenues for treatment of numerous eye diseases.
Rhodopsin-bound nanobodies

UC Irvine researchers discover a nanobody which may lead to treatment for retinitis pigmentosa

University of California Irvine (UCI) researchers believe they have discovered a special antibody that may lead to a treatment for an inherited eye disease called retinitis pigmentosa.

Want more news from NEI?

Connect with us through social media to stay up to date on vision research, eye health, and other topics!

NEI Press Office

We can connect media professionals with the latest vision research info. Get in touch!


Phone: 301-496-5248